FRONTLINE becomes Brand of the Year 2019-2020
FRONTLINE ®becomes ‘Brand of the Year’ 2019-2020 in World Branding AwardsFRONTLINE ® was named global ‘Brand of the Year’ (Animalis Edition) for 2019-2020The Award scores are predominantly constituted by consumer votesWorld Branding Awards recognise and celebrate some of the best global, regional and national brands for their work and achievement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 1, 2019 Category: Research Source Type: news

Collaboration with Yuhan Corporation on NASH
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan CorporationBoehringer Ingelheim focuses on the development of next generation NASH treatments that target all three key drivers of the disease - steatosis, inflammation and fibrosisCollaboration aims to develop first-in-class dual agonist (GLP1R/FGF21R agonist) for NASHYuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 1, 2019 Category: Research Source Type: news

FDA-fast-track-designation-chronic-heart-failure
US FDA grants Fast Track designation to empagliflozin for the treatment of chronic heart failureFast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need.  FDA ’s Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 26 million people affected by chronic heart failure worldwide, including 6.5 million in the US.1,2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 26, 2019 Category: Research Source Type: news

12th Expert Forum on Farm Animal Well-Being
Collaboration key to meeting consumers ’ expectations for better animal welfareThe 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts to discuss the latest trends, challenges and opportunities in the industryBy organising such events, Boehringer Ingelheim demonstrates its continuous commitment to and leadership in improving animal welfare (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 18, 2019 Category: Research Source Type: news

BI 765064 SIRP α-antibody Phase I started
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRP α Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid TumorsFirst-in-class checkpoint inhibitor BI 765063 licensed to and being developed under a collaboration agreement between Boehringer Ingelheim and OSE ImmunotherapeuticsClinical Trial Authorization and dosing of the first patient triggers a total of €15 million milestone payments from Boehringer Ingelheim to OSE Immunotherapeutics (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 17, 2019 Category: Research Source Type: news

Winners of BVDzero Scholarship Programme
Boehringer Ingelheim announces winners of BVDzero Scholarship ProgrammeThe aim of this initiative is to increase bovine viral diarrhoea (BVD) awareness among veterinary studentsThis programme has been implemented in collaboration with the World Association for Buiatrics, as an incentive to participate in the World Buiatrics Congress 2020 in Madrid (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 14, 2019 Category: Research Source Type: news

Boehringer Ingelheim relies on digital transformation
The healthcare of tomorrow:   Boehringer Ingelheim relies on digital transformationDigital Health makes the treatment, prevention, and early detection of diseases faster and more preciseHealthcare solutions of the future were discussed at the re:publica digital conferenceBoehringer Ingelheim calls for improved framework conditions for digitalization in the healthcare industry  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 11, 2019 Category: Research Source Type: news

Boehringer Ingelheim extends PROTAC Discovery Program
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer AllianceBoehringer Ingelheim and University of Dundee achieve milestone in collaboration aimed at developing novel protein degradation medicinesResults published in Nature Chemical Biology showcase the use of the broadly applicable structure-based PROTAC design approach to discover highly potent and selective drug candidatesThe first PROTAC is made freely available via Boehringer Ingelheim ’s open innovation portal, opnMeStructure-based PROTAC design promises to accelerate the developm...
Source: Boehringer Ingelheim Corporate News - June 11, 2019 Category: Research Source Type: news

CAROLINA-full-data
Full data from CAROLINA ® outcome trial support long-term cardiovascular safety profile of Trajenta®CAROLINA ® demonstrated no increased cardiovascular risk for Trajenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor Adults with diabetes treated with Trajenta ® experienced significantly fewer events of hypoglycaemia and a modest weight reduction compared to patients treated with glimepiride Detailed results from CAROLINA ® were presented at the American Diabetes Association’s 79th Scientific ...
Source: Boehringer Ingelheim Corporate News - June 11, 2019 Category: Research Source Type: news

type-2-diabetes-cardiorenal-post-hoc-analysis
New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuriaFindings from a post-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and chronic kidney disease without overt proteinuria were presented at the 79th American Diabetes Association Scientific Sessions® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 10, 2019 Category: Research Source Type: news

Partnering with Constantia Flexibles for augmented reality packaging experience
Boehringer Ingelheim partners with Constantia Flexibles to provide augmented reality packaging experienceThe packaging of Nutraxin, a nutritional supplement for horses, is now equipped with augmented reality and interactive featuresThis partnership reaffirms Boehringer Ingelheim ’s continuous focus on providing innovative solutions to its customers (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 4, 2019 Category: Research Source Type: news

Boehringer Ingelheim_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch digital healthcare program in KenyaNew digital disease management program “Tiba Yako” breaks access and awareness barriers in hypertension and diabetes careThe mobile-based technology allows patients to monitor their blood pressure and blood glucose levels at home, digitally sending the results to their doctor  Tiba Yako is an integrated disease service model that will offer benefits to patients, healthcare providers and payers alike    There is an unmet need for efficient affordable and widely accessible care for hypertension and diabetes in Kenya1,2&n...
Source: Boehringer Ingelheim Corporate News - June 3, 2019 Category: Research Source Type: news

New collaboration with Gubra on obesity treatment
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonistsObesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options availableNew collaboration aims to develop novel peptide poly-agonists for the treatment of obesity and concomitant diseasesGubra may receive up to EUR 240 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 29, 2019 Category: Research Source Type: news

New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platformIt is the first comprehensive ‘industry-academia-research’ exchange platform jointly set up by an agricultural research institute and a multinational animal health company in ChinaPartners join forces to foster the integration of the industry, academia and research (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 22, 2019 Category: Research Source Type: news

Network-of-1500-stroke-ready-clinics-across-Europe
Network of 1,500 stroke-ready clinics across Europe  The award-winning Angels Initiative delivers on its three-year goal to create a network of more than 1,500 stroke-ready clinics across EuropeSince 2016, a total of 2,700 clinics worldwide are now part of the Angels InitiativeThe ESO Angels Awards praise 331 clinics in several countries who have made great steps in optimising stroke care for patients locally (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 22, 2019 Category: Research Source Type: news

nintedanib slows pulmonary function loss in people with ssc-ild
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1Results of pivotal Phase III SENSCIS ®trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USAInterstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3FDA grants priority review to application for regulatory approval for nintedanib in patients ...
Source: Boehringer Ingelheim Corporate News - May 20, 2019 Category: Research Source Type: news

Veterinary oncology experts meet in Germany
Veterinary oncology experts from Europe, Japan and the US meet in GermanyVeterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, GermanyThe collaboration between Boehringer Ingelheim and the Veterinary Oncology Advisory Board focuses on developing unparalleled therapeutic solutions for the veterinary community and establishing new standards of care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 20, 2019 Category: Research Source Type: news

NOAC-vs-ASA-in-ESUS-trial-results-published-in-NEJM
Trial results of Pradaxa ® vs ASA in ESUS published in NEJMFirst Phase III randomised clinical trial to compare dabigatran etexilate and acetylsalicylic acid (ASA)  No significant difference in recurrent stroke prevention after ESUSDabigatran showed no significant difference in major bleeding (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 16, 2019 Category: Research Source Type: news

Boehringer Ingelheim fosters cooperation with innovative partners
Digital transformation: Boehringer Ingelheim fosters cooperation with innovative partnersDigital technologies can contribute to improved monitoring, more rapid diagnosis, and more successful treatmentPilot project with Belgian start-up SoundTalks facilitates disease prevention among farm animals  Open innovation online portal promotes collaboration with external partners in research and development   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 14, 2019 Category: Research Source Type: news

Accelerator_program_mmh
Boehringer Ingelheim announces finalists of the Making More Health Accelerator ProgramBoehringer Ingelheim to support scale up of two projects of its Making More Health (MMH) Accelerator Program.The Accelerator Program aims to help early stage enterprises develop sustainable care delivery models. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 2, 2019 Category: Research Source Type: news

annual_results_press_conference_2019
Financial year 2018:  Boehringer Ingelheim grows and invests Well-filled research pipeline in oncology, fibrotic diseases, immunology and metabolic diseasesOperating growth outpaces the market in all businessesTechnical integration of the animal health business acquired in 2017 successfully completed (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 16, 2019 Category: Research Source Type: news

Boehringer Ingelheim acquires a stake in SoundTalks
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme Boehringer Ingelheim plans a pilot programme using the innovative SoundTalksTM system in select pig barnsThe goal is to harness the power of digital innovation and technological change to detect possible respiratory distress in swine quickly (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 15, 2019 Category: Research Source Type: news

Real-world-study-comparing-NOACs-in-AF-patients
Independent large real-world study comparing NOACs in AF-patientsA recently published large retrospective comparative study investigated stroke, bleeding and mortality risks in older US Medicare patients treated with commonly marketed oral anticoagulants for non-valvular atrial fibrillation1  Results of the real-world study showed that Pradaxa ® (dabigatran etexilate) was associated with a more favourable benefit-risk profile in comparison to both warfarin and rivaroxaban1Data from an earlier FDA-funded Medicare study published in 2015, which investigated cardiovascular, bleeding and mortality risks among patients...
Source: Boehringer Ingelheim Corporate News - April 15, 2019 Category: Research Source Type: news

effectiveness-analysis-in-diabetic-kidney-disease-and-type-2-diabetes
New post-hoc analysis of EMPA-REG OUTCOME ® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1  Cost effective analysis used modeling and simulations based on subgroup data from EMPA-REG OUTCOME ® to predict clinical events and estimated costs for people with type 2 diabetes and diabeti...
Source: Boehringer Ingelheim Corporate News - April 15, 2019 Category: Research Source Type: news

Celebrating 20 years of Metacam for cattle
Boehringer Ingelheim celebrates 20 years of Metacam ® for cattle2019 marks the anniversary of Metacam ® (meloxicam) for cattleOriginally licenced for dogs, Metacam ®can be used in other species to treat inflammatory and painful conditionsBoehringer Ingelheim celebrates this 20-year milestone since pioneering meloxicam for use in both humans and animals (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2019 Category: Research Source Type: news

Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and DortmundEuropean launches of next-generation inhaler kicked off  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2019 Category: Research Source Type: news

Arti-cell Forte stem cell-based veterinary product
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicineEuropean Commission has granted marketing authorisation for the first stem cell-based product in animal healthArti-Cell ® Forte is a unique ready-to-use solution for the treatment of equine lamenessThe partnership of Boehringer Ingelheim and GST proves its commitment to bring highly innovative therapeutics for horses to customers (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 7, 2019 Category: Research Source Type: news

‘uniqueness’ by championing both human and animal health
Boehringer Ingelheim celebrates its ‘uniqueness’ by championing both human and animal health in new campaign Boehringer Ingelheim changes perception due to its dedication to human and animal health“A Unique Bond” explores stories of the positive impact animals can have on patient’s lives  Launched in 28 countries, the company affirms its dedication to both human and animal health with local initiatives   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 3, 2019 Category: Research Source Type: news

Positivity... just a paw away
Positivity … just a paw awayOwners claim that their pet has a strong positive impact on their daily lives.1   According to experts, “pets benefit the lives of their owners, both psychologically and physically”.2 Acknowledging this, Boehringer Ingelheim launches global initiatives to improve the positivity of their employees, patients and animals alike. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 3, 2019 Category: Research Source Type: news

Why we may be more like our pets than we think
Like their owners, pets are living longer1  and are prone to conditions such as cancer and obesity.2,3,4Recent data exploring the human-animal connection shows that pets are integral to improving our quality of life.5A global campaign reveals the remarkable bond between people and animals, and how pets can help provide support through illness as well as recovery.6   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 2, 2019 Category: Research Source Type: news

Launch of BVDzero scholarship for veterinary students
Boehringer Ingelheim launches BVDzero scholarship for veterinary students globallyBoehringer Ingelheim grants a total BVDzero scholarship of 10,000 euro to top 10 students worldwideThe company  aims to increase bovine viral diarrhea (BVD) awareness among veterinary studentsThis initiative is implemented in collaboration with the World Association for Buiatrics, as an incentive to participate in the World Buiatrics Congress 2020 in Madrid    (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 29, 2019 Category: Research Source Type: news

Acquisition Saint-Herblon site and Coophavet brand
Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production siteThe acquisition includes the Saint-Herblon production site and the Coophavet brandThe sale is part of the Boehringer Ingelheim ’s strategic refocusing on advanced and preventive animal healthcare (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 29, 2019 Category: Research Source Type: news

Acquisition of novel oncology delivery technology
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD TherapeuticsNew molecular platform to access intracellular targets across a broad range of tumor cell typesOpens up new range of therapeutic opportunities for difficult-to-treat cancers   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 29, 2019 Category: Research Source Type: news

EMPRISE real-world study results
Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019  EMPRISE is an ongoing real-world evidence study in 35,000 people with type 2 diabetes in the US, comparing empagliflozin with DPP-4 inhibitors; initial results based on the first two years of the study were presented at AMCP 2019 and ACC.191,2Initial results presented at AMCP 2019 showed empagliflozin was associated with reductions in all-cause hospitalisations compared with DPP-4 inhibitors, and significantly fewer recurrent emergency department visits and physician office visits1Initia...
Source: Boehringer Ingelheim Corporate News - March 28, 2019 Category: Research Source Type: news

World water day 2019
World Water Day - Making every drop countBoehringer Ingelheim started a social project in Mexico City to preserve the aquifer and to ensure the water supply for dog shelters  First rainwater collector and filter will save 180,000 liters of rainwater every yearPublic campaign also promotes sterilization and adoption of   shelter dogs (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 20, 2019 Category: Research Source Type: news

FDA-and-EMA-regulatory-submission-nintedanib-in-SSc-ILD
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILDSystemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue diseasePulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need1,2Improving the lives of people living with pulmonary fibrosis is a key focus for Boehringer Ingelheim (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 15, 2019 Category: Research Source Type: news

NEJM-IL-36-Phase-1-GPP-data
Novel antibody shows potential to transform treatment of rare form of psoriasisPublished in The New England Journal of Medicine, new data show single dose BI 655130* rapidly cleared symptoms of a rare and potentially life-threatening form of pustular psoriasis1BI 655130 is an investigational, potential first-in-class treatment targeting interleukin-36 receptor (IL-36R)BI 655130 is being studied in generalised pustular psoriasis as the first of several potential indications, including inflammatory bowel diseases  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 6, 2019 Category: Research Source Type: news

Launch of Frontline flagship store on Tmall
Boehringer Ingelheim launches Frontline Flagship Store on TmallBoehringer Ingelheim launches its flagship store on an e-commerce platform TmallThe store specialises on the company ’s full range of pet parasiticidesBoehringer Ingelheim recognises e-commerce as paramount for its growth in China (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 27, 2019 Category: Research Source Type: news

Boehringer Ingelheim partners with GNA Biosolutions
Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics developmentProgramme could lead to new diagnostic solutions for African swine feverBoehringer Ingelheim demonstrates its focus on prevention and innovation yet again (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 22, 2019 Category: Research Source Type: news

New Chief Medical Officer appointed
  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 22, 2019 Category: Research Source Type: news

Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Blockchain technology has the potential to improve trust, transparency, patient safety and patient empowerment in clinical trials (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 12, 2019 Category: Research Source Type: news

CAROLINA-top-line
For non-US, non-UK audiences (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 4, 2019 Category: Research Source Type: news

Boehringer Ingelheim leader in hatchery vaccination with vector vaccines
Boehringer Ingelheim reaffirms its leading position in hatchery vaccination with its vector vaccines at IPPE 2019Vaxxitek ® HVT + IBD continues to lead in hatchery vector vaccination worldwideNewxxitek ® HVT + ND is Boehringer Ingelheim’s latest vectored vaccine against Newcastle disease (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 4, 2019 Category: Research Source Type: news

Launch of first veterinary vaccines produced in China
Boehringer Ingelheim launches first veterinary vaccines produced in ChinaThe first local manufacturing plant, wholly-owned by a multinational animal health company, focuses on the China swine marketThe Taizhou plant will produce PRRS vaccines and supply them locallyThe company delivers on its long-term ‘in China, for China’ commitment while accelerating its localisation strategy (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 24, 2019 Category: Research Source Type: news

Boehringer_ingelheim_partners_with_ampath_in_Kenya
Boehringer Ingelheim partners with AMPATH to scale up knowledge, skills and training for healthcare providers in KenyaPartnership with AMPATH aims to advance Boehringer Ingelheim ’s Healthcare Initiative In Reach Africa Collaboration partnership to build a holistic and sustainable health system in Kenya  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 23, 2019 Category: Research Source Type: news

A_Healthy_2019
A healthy 2019: Four paws for more relaxation and exerciseAn international study confirms that the emotional bonds between people and their pets enhance health and well-beingOver 90 percent of pet owners say their animals have a positive effect on their quality of lifePets also help people stick to their New Year ’s resolutions  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 21, 2019 Category: Research Source Type: news

Capacity_expansion_OASIS
Boehringer Ingelheim Biopharmaceuticals China expands commercial manufacturing capacitiesExpansion of manufacturing capacities in OASIS facilityIncreasing demands for world-class manufacturing in Shanghai, ChinaFirst commercial product manufacturing in Shanghai expected in 2019  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 17, 2019 Category: Research Source Type: news

Second Dicerna Hepatic Disease Target Option Exercise
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target  From Research Collaboration with Dicerna Collaboration seeks to develop novel treatments for chronic liver diseases,  including nonalcoholic steatohepatitis (NASH)  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 4, 2019 Category: Research Source Type: news

Collaboration with Vanderbilt University
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders  Boehringer Ingelheim Enhances Central Nervous System Disease PipelineVanderbilt Center for Neuroscience Drug Discovery Advances Preclinical Schizophrenia Targets   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 3, 2019 Category: Research Source Type: news

Virtual clinical trial collaboration with Science 37
Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies  Boehringer Ingelheim collaborates with Science 37 to accelerate the clinical development of new therapies worldwide  Science 37 ’s technology enables patients to remotely participate in clinical studies, which enables increased patient diversity, study efficiency and speed, while decreasing patient burden (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 3, 2019 Category: Research Source Type: news